Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stock Downgraded By Second Bank in Two Months

NEW YORK, Aug. 4 (GenomeWeb News) - Merriman Curhan Ford today downgraded Ciphergen shares to 'sell' from 'neutral,' the the brokerage and investment bank said.

 

The downgrade comes as Ciphergen shares continue to slide after the company reported lackluster sales during the second quarter.

 

The downgrade is the second in as many months to hit Ciphergen: Piper Jaffray on July 1 downgraded the stock to 'underperform' from 'outperform.'

 

Shares in the Fremont, Calif.-based protein chip company were trading down 15.5 percent, or $.49, at $2.87 on the Nasdaq exchange late this morning. The shares closed at $4.10 on July 30. Ciphergen issued its second-quarter earnings after the market closed that day.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.